Blackrock’s Sending THIS Crypto Higher on Purpose

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Simon Benito Biography and Net Worth

Director of Inovio Pharmaceuticals

Simon X. Benito serves as Independent Chairman of the Board of the Company. He has served on our Board since December 2003 and qualifies to serve on our Board as he brings to our Board formal accounting and financial training and expertise, significant public company board experience, senior management experience in the health care industry, and important industry contacts. Prior to his retirement, Mr. Benito had a successful and extensive career serving several multinational corporations in senior executive positions, including 25 years at Merck & Company, Inc. His most recent positions included Senior Vice President, Merck Vaccine Division; Executive Vice President, Merck-Medco Managed Care; and Executive Director and Vice President, Merck Human Health, Japan. In addition, Mr. Benito was a Fellow of the Institute of Chartered Accountants in England and Wales for over 30 years until his retirement in 1999. Since April 2005, Mr. Benito has served as a director of DURECT Corporation, a publicly traded specialty pharmaceutical company.

What is Simon X. Benito's net worth?: The estimated net worth of Simon X. Benito is at least $2,161.08 as of July 20th, 2022. Mr. Benito owns 522 shares of Inovio Pharmaceuticals stock worth more than $2,161 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Benito may own. Learn More about Simon X. Benito's net worth.
How do I contact Simon X. Benito?: The corporate mailing address for Mr. Benito and other Inovio Pharmaceuticals executives is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. Inovio Pharmaceuticals can also be reached via phone at (267) 440-4200 and via email at [email protected]. Learn More on Simon X. Benito's contact information.
Has Simon X. Benito been buying or selling shares of Inovio Pharmaceuticals?: Simon X. Benito has not been actively trading shares of Inovio Pharmaceuticals during the last quarter. Most recently, Simon X. Benito sold 13 shares of the business's stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $324.00, for a transaction totalling $4,212.00. Following the completion of the sale, the director now directly owns 522 shares of the company's stock, valued at $169,128. Learn More on Simon X. Benito's trading history.
Who are Inovio Pharmaceuticals' active insiders?: Inovio Pharmaceuticals' insider roster includes Simon Benito (Director), Laurent Humeau (Insider), Peter Kies (CFO), Jong Kim (CEO), Jacqueline Shea (COO), David Weiner (Director), and Lota Zoth (Director). Learn More on Inovio Pharmaceuticals' active insiders.

Simon X. Benito Insider Trading History at Inovio Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/20/2022	Sell	13	$324.00	$4,212.00	522
3/16/2022	Sell	13	$455.04	$5,915.52
1/19/2022	Sell	13	$614.88	$7,993.44
4/16/2021	Sell	13	$1,260.00	$16,380.00	372
3/16/2021	Sell	13	$1,499.04	$19,487.52
4/12/2018	Sell	26	$753.12	$19,581.12	219
5/18/2016	Sell	43	$1,493.28	$64,211.04	167
8/14/2015	Buy	41	$1,038.24	$42,567.84

Simon X. Benito Buying and Selling Activity at Inovio Pharmaceuticals

Inovio Pharmaceuticals Company Overview

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Today's Range

Now: $4.14

$3.97

$4.24

50 Day Range

MA: $5.61

$3.97

$6.82

2 Week Range

Now: $4.14

$3.85

$14.75

Volume

328,307 shs

Average Volume

403,938 shs

Market Capitalization

$108.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83